• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析:该文本的译文为“Tirzepatide 和肽 20 与 GIP、GLP-1 或胰高血糖素受体的多重药理作用的结构见解。” 解析:原文中“Structural insights”翻译为“结构见解”,“multiplexed pharmacological actions”翻译为“多重药理作用”,“GIP”翻译为“GIP”,“GLP-1”翻译为“GLP-1”,“glucagon receptors”翻译为“胰高血糖素受体”。

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.

机构信息

School of Pharmacy, Fudan University, Shanghai, China.

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

出版信息

Nat Commun. 2022 Feb 25;13(1):1057. doi: 10.1038/s41467-022-28683-0.

DOI:10.1038/s41467-022-28683-0
PMID:35217653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8881610/
Abstract

Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their multiplexed pharmacological actions over monoagonists such as semaglutide, we determine cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR. The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the near-atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility of tirzepatide and peptide 20.

摘要

葡萄糖稳态受葡萄糖依赖性胰岛素释放多肽 (GIP)、胰高血糖素样肽-1 (GLP-1) 和胰高血糖素 (GCG) 调节,对人类健康至关重要。几种针对 GIPR、GLP-1R 或 GCGR 的多靶点激动剂已被开发出来,以最大限度地提高代谢益处,同时减少副作用,目前正在临床试验中用于治疗 2 型糖尿病和肥胖症。为了阐明替西帕肽(一种 GIPR/GLP-1R 双重激动剂)和肽 20(一种 GIPR/GLP-1R/GCGR 三激动剂)发挥其多效药理学作用的分子机制,超过诸如司美格鲁肽等单激动剂,我们确定了与 GIPR 和 GLP-1R 结合的替西帕肽以及与 GIPR、GLP-1R 和 GCGR 结合的肽 20 的冷冻电子显微镜结构。这些结构通过在近原子水平上阐明与临床相关的关键相互作用,揭示了双重和三重激动作用的共同和独特特征。保留胰高血糖素的功能对于优于 GLP-1 单药治疗是必需的。我们的研究结果为替西帕肽和肽 20 的功能多功能性的结构基础提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/2b48d24c413f/41467_2022_28683_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/882fd6fac020/41467_2022_28683_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9429ae0600b6/41467_2022_28683_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/b628f38969bf/41467_2022_28683_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9d6d4053f313/41467_2022_28683_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9359deb9417d/41467_2022_28683_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/da85de4e5ff9/41467_2022_28683_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/2b48d24c413f/41467_2022_28683_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/882fd6fac020/41467_2022_28683_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9429ae0600b6/41467_2022_28683_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/b628f38969bf/41467_2022_28683_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9d6d4053f313/41467_2022_28683_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/9359deb9417d/41467_2022_28683_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/da85de4e5ff9/41467_2022_28683_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26d7/8881610/2b48d24c413f/41467_2022_28683_Fig7_HTML.jpg

相似文献

1
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.解析:该文本的译文为“Tirzepatide 和肽 20 与 GIP、GLP-1 或胰高血糖素受体的多重药理作用的结构见解。” 解析:原文中“Structural insights”翻译为“结构见解”,“multiplexed pharmacological actions”翻译为“多重药理作用”,“GIP”翻译为“GIP”,“GLP-1”翻译为“GLP-1”,“glucagon receptors”翻译为“胰高血糖素受体”。
Nat Commun. 2022 Feb 25;13(1):1057. doi: 10.1038/s41467-022-28683-0.
2
Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.人心外膜脂肪组织表达葡萄糖依赖性胰岛素促分泌多肽、胰高血糖素和胰高血糖素样肽-1 受体,作为多效治疗的潜在靶点。
Eur J Prev Cardiol. 2023 Jun 1;30(8):680-693. doi: 10.1093/eurjpc/zwad050.
3
An update on peptide-based therapies for type 2 diabetes and obesity.关于 2 型糖尿病和肥胖症的基于肽的治疗方法的最新进展。
Peptides. 2023 Mar;161:170939. doi: 10.1016/j.peptides.2023.170939. Epub 2023 Jan 3.
4
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.新一代 GLP-1/GIP/胰高血糖素三重激动剂可使肥胖小鼠体重正常化。
Mol Metab. 2022 Sep;63:101533. doi: 10.1016/j.molmet.2022.101533. Epub 2022 Jul 7.
5
Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.GIP 和 GLP-1 受体的单肽、双肽和三肽激动剂的药理学特性。
Biochem Pharmacol. 2020 Jul;177:114001. doi: 10.1016/j.bcp.2020.114001. Epub 2020 Apr 29.
6
GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.GLP-1 和 GIP 受体在β细胞中的信号转导 - 受体相互作用和共刺激的综述。
Peptides. 2022 May;151:170749. doi: 10.1016/j.peptides.2022.170749. Epub 2022 Jan 19.
7
A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.一种双重 GLP-1/GIP 受体激动剂不会在其受体上拮抗胰高血糖素,而是可能在 GLP-1 受体上作为一种偏向激动剂发挥作用。
Int J Mol Sci. 2019 Jul 19;20(14):3532. doi: 10.3390/ijms20143532.
8
Structural determinants of dual incretin receptor agonism by tirzepatide.替西帕肽对双重肠促胰岛素受体激动作用的结构决定因素。
Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119. doi: 10.1073/pnas.2116506119. Epub 2022 Mar 25.
9
Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.基于 Xenopus GLP-1 的长效订书钉状双重 GLP-1/胰高血糖素受体激动剂,具有治疗代谢疾病的强大疗效。
Mol Pharm. 2021 Aug 2;18(8):2906-2923. doi: 10.1021/acs.molpharmaceut.0c00995. Epub 2021 Jul 9.
10
Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.胰高血糖素样肽-1受体相互作用与转运的功能后果
J Biol Chem. 2015 Jan 9;290(2):1233-43. doi: 10.1074/jbc.M114.592436. Epub 2014 Dec 1.

引用本文的文献

1
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.对卡格列净肽在胰淀素和降钙素受体中双重激活的结构和机制见解。
Acta Pharmacol Sin. 2025 Aug 22. doi: 10.1038/s41401-025-01635-2.
2
Lighting up targets of dual agonist therapies for diabetes and obesity.点亮糖尿病和肥胖症双重激动剂疗法的靶点。
Nat Metab. 2025 Aug;7(8):1507-1508. doi: 10.1038/s42255-025-01346-2.
3
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.荧光GLP1R/GIPR双激动剂探针揭示胰腺和大脑中的细胞靶点。

本文引用的文献

1
Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.与 semaglutide 和 taspoglutide 结合的 GLP-1R-Gs 复合物的结构和动力学。
Cell Rep. 2021 Jul 13;36(2):109374. doi: 10.1016/j.celrep.2021.109374.
2
Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor.人类葡萄糖依赖性胰岛素促分泌多肽受体识别激素的结构见解。
Elife. 2021 Jul 13;10:e68719. doi: 10.7554/eLife.68719.
3
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Nat Metab. 2025 Aug 19. doi: 10.1038/s42255-025-01342-6.
4
Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.替尔泊肽与其他抗肥胖药物在肥胖人群中的眼部比较结果。
Commun Med (Lond). 2025 Aug 1;5(1):329. doi: 10.1038/s43856-025-01066-4.
5
Binding of Soluble Ligands to Membrane Receptors: A Molecular Dynamics Simulation Study.可溶性配体与膜受体的结合:分子动力学模拟研究
J Phys Chem B. 2025 Jul 24;129(29):7475-7482. doi: 10.1021/acs.jpcb.5c01197. Epub 2025 Jul 12.
6
Heat-Inactivated pA1cHI Maintains Glycemic Control and Prevents Body Weight Gain in High-Fat-Diet-Fed Mice.热灭活的pA1cHI可维持高脂饮食喂养小鼠的血糖控制并防止体重增加。
Int J Mol Sci. 2025 Jul 3;26(13):6408. doi: 10.3390/ijms26136408.
7
Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application.肽配体激活的G蛋白偶联受体信号转导的结构见解:从分子机制到治疗应用
Exp Mol Med. 2025 Jul 8. doi: 10.1038/s12276-025-01497-y.
8
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.超越胰高血糖素样肽-1:双重和三重肠促胰岛素激动剂在2型糖尿病个性化治疗中的疗效和安全性——一项系统评价与网状Meta分析
Acta Diabetol. 2025 Jun 5. doi: 10.1007/s00592-025-02534-y.
9
The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort.司美格鲁肽和替尔泊肽引发前庭疾病的风险:来自大型真实世界队列的研究结果
Biomedicines. 2025 Apr 26;13(5):1049. doi: 10.3390/biomedicines13051049.
10
Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation.通过肽脂化在体外和体内延长甲状旁腺激素类似物的作用。
Nat Commun. 2025 May 14;16(1):4487. doi: 10.1038/s41467-025-59665-7.
替尔泊肽与司美格鲁肽每周一次治疗 2 型糖尿病患者的疗效比较。
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
4
Breaking New Ground with Incretin Therapy in Diabetes.糖尿病肠促胰岛素疗法开辟新领域
N Engl J Med. 2021 Aug 5;385(6):560-561. doi: 10.1056/NEJMe2109957. Epub 2021 Jun 25.
5
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.解析人胰高血糖素样肽-1 受体变构调节剂的分子机制。
Nat Commun. 2021 Jun 18;12(1):3763. doi: 10.1038/s41467-021-24058-z.
6
Molecular basis of ligand recognition and activation of human V2 vasopressin receptor.人V2血管加压素受体的配体识别与激活的分子基础
Cell Res. 2021 Aug;31(8):929-931. doi: 10.1038/s41422-021-00480-2. Epub 2021 Mar 19.
7
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
8
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.受选定的受体单激动剂和双重激动剂诱导的 GLP-1 和 GIP 受体的时空信号转导和转运/再循环动力学。
Mol Metab. 2021 Jul;49:101181. doi: 10.1016/j.molmet.2021.101181. Epub 2021 Feb 6.
9
G protein-coupled receptors: structure- and function-based drug discovery.G 蛋白偶联受体:基于结构和功能的药物发现。
Signal Transduct Target Ther. 2021 Jan 8;6(1):7. doi: 10.1038/s41392-020-00435-w.
10
A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor.人胰高血糖素样肽-2 受体的独特激素识别特征。
Cell Res. 2020 Dec;30(12):1098-1108. doi: 10.1038/s41422-020-00442-0. Epub 2020 Nov 25.